The U.S. Supreme Court today declined to hear Johnson & Johnson‘s (NYSE:JNJ) appeal of a $302 million judgment for false and deceptive marketing of its vaginal mesh implants. The nation’s highest court denied the medtech maker’s bid for review without comment, allowing the California ruling to stand. Attorneys for the state sued Johnson & Johnson […]
pelvic mesh
J&J settles big Australian pelvic mesh case
Johnson & Johnson (NYSE: JNJ) has settled an Australian pelvic mesh class action suit for AU$300 million (roughly U.S. $205 million), according to media reports. Shine Lawyers, which handled the suit, confirmed the settlement. It still requires court approval. More than 11,000 claimants in Australia had sought relief, according to Reuters. In a statement shared […]
Coloplast wins summary judgement in transvaginal mesh suit in Minnesota
A federal judge in Minnesota granted summary judgment to Coloplast in a lawsuit over the company’s transvaginal mesh. Angela Dawn Cantrell received the Restorelle L mesh implant as part of surgery to correct vaginal prolapse in January 2018. Cantrell continued to experience pain and pelvic floor dysfunction after the surgery and underwent additional surgeries. In […]
California appeals court orders Johnson & Johnson to pay $302M in pelvic mesh case
A California appeals court mostly agreed that Johnson & Johnson must pay the state hundreds of millions of dollars over misleading marketing around the risks of pelvic mesh products. The Fourth District Court of Appeals in California, in its April 11 ruling, reduced the size of the civil penalties against J&J’s Ethicon subsidiary by $42 […]
AdvaMed supports effort to overturn J&J pelvic mesh ruling in California
Medical device trade group AdvaMed announced today that it has filed an amicus curiae brief supporting an appeal to overturn a $344 million pelvic mesh ruling against Johnson & Johnson in California. Lawyers for AdvaMed tell the California Court of Appeal that the San Diego Superior Court judgment violated safe harbor protections because the case involved […]
Boston Scientific settles host of state pelvic mesh lawsuits for nearly $189M
Boston Scientific (NYSE:BSX) has agreed to pay $188.6 million to 47 states and the District of Columbia to resolve claims that it deceptively marketed transvaginal surgical mesh devices, state AGs announced today. Pelvic mesh products have been one of the medical device industry’s worst failures so far in the 21st century. First cleared nearly two […]
N.J. appeals court tosses $83M pelvic mesh verdicts against J&J, Bard
A New Jersey appeals court yesterday threw out jury verdicts totaling $83 million in separate pelvic mesh lawsuits against Johnson & Johnson’s (NYSE:JNJ) Ethicon division and Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard. In both cases, Bergen County, N.J. judges erred by disallowing evidence showing that each company’s mesh product had received FDA 510 (k) clearance, according […]
Federal lawsuit over Boston Sci pelvic mesh heads to trial
A federal judge in Arkansas has ruled that most counts in a pelvic mesh lawsuit against Boston Scientific can go to trial. Kortney Cline sued Boston Sci in 2014, claiming that she suffered injuries after implantation with the company’s Obtryx trans-obturator mid-urethral sling in 2009. Cline’s case was recently transferred to federal court in Arkansas […]
BD is paying $60M to settle Bard pelvic mesh suits with most U.S. states
Becton Dickinson (NYSE:BDX) will pay $60 million to 48 U.S. states to resolve allegations that its C.R. Bard business deceptively marketed transvaginal surgical mesh devices, state attorneys general in California and Washington announced today. Mesh products were meant to treat the weakening of the muscles and ligaments supporting a woman’s pelvic organs, but they instead sparked […]
Study: FDA should have banned pelvic mesh long before it did
Researchers who conducted a long-term study of women implanted with transvaginal mesh to treat pelvic organ prolapse (POP) concluded that the FDA should have banned the product sooner than it did. The study of 54,194 women in New York State revealed that women treated with mesh had an 8.8% risk of reintervention 5 years after […]
